# A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Source: https://onco.cc/trials/nct02912949/  
OnCo record `nct02912949` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zenocutuzumab in non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Partner Therapeutics, Inc., active and no longer recruiting.

## Summary

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) is a phase 2 interventional study registered as NCT02912949 by Partner Therapeutics, Inc., with 250 participants enrolled, started 2015-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: zenocutuzumab (MCLA-128).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02912949
- Phase: 2
- Setting: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
- Sponsor: Partner Therapeutics, Inc.
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT02912949: https://clinicaltrials.gov/study/NCT02912949

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/)
- companies: [Partner Therapeutics](https://onco.cc/companies/partner-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02912949.json